Arriving in the arena of obesity treatment, retatrutide presents a unique method. Unlike many current medications, retatrutide operates as a dual agonist, at once targeting both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic substance (GIP) receptors. This concurrent stimulation encourages several advantageous effects, includi